In the present study, we analyzed the impact of BCR-ABL+ ALL on the heart, as well as the effect of targeted anti-cancer therapy with DAS, DEX and VEN on the functional and molecular levels. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.